Market Flux Event

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion in Cash

Read this in the Market Flux app

Eli Lilly agreed on November 16, 2026, to acquire privately held Calytrix Bio for up to $1.5 billion in cash. The deal includes an upfront payment whose size was not disclosed, plus additional payments contingent on clinical trial and regulatory milestones. No expected closing date was provided.

Calytrix, founded just last year by J.P. Morgan Life Sciences Private Capital and backed by Westlake BioPartners and Avoro Ventures, is developing an experimental antibody that targets mutant calreticulin, known as mCALR. This protein is a genetic driver of two blood cancers: essential thrombocythemia and myelofibrosis. The lead therapy is designed to attack the cells driving those diseases while sparing healthy tissue, distinguishing it from existing treatments that largely manage symptoms rather than their cellular source.

© AI-generated summary is provided by Market Flux

Sources

  1. FirstSquawkLILLY TO BUY CALYTRIX BIO FOR UP TO $1.5B IN CASH
  2. WallstengineELI LILLY $LLY TO ACQUIRE CALYTRIX BIO FOR UP TO $1.5 BILLION IN CASH The deal includes an upfront payment and additional payments tied to clinical and regulatory milestones. The upfront amount was not disclosed. Calytrix is developing an experimental antibody targeting mutant calreticulin (mCALR), a genetic driver of two blood cancers, essential thrombocythemia and myelofibrosis. Unlike existing treatments that primarily manage symptoms, its lead therapy is designed to target the cells driving the disease while preserving healthy tissue. Calytrix was founded just last year by J.P. Morgan Life Sciences Private Capital, with financing backed by Westlake BioPartners and Avoro Ventures.
  3. BioStocks$LLY to acquire Calytrix Bio for up to $1.5B in cash
  4. ReutersLilly to buy Calytrix Bio for up to $1.5 billion
  5. PiQMarketsEli Lilly agrees to buy Calytrix Bio for up to $1.5 billion Eli Lilly agreed on November 16, 2026, to acquire privately held Calytrix Bio for up to $1.5 billion in cash, Calytrix said. The deal pairs an upfront payment with payments tied to clinical trial and regulatory milestones, and Calytrix did not disclose the upfront size or an expected closing date.
  6. InvestingEli Lilly to buy Calytrix Bio for up to $1.5 bln
  7. Marketsday$LLY Lilly To Acquire Closely Held Neoplasm Therapy Developer Calytrix Bio For Up To $1.5B In Cash
  8. NasdaqCalytrix Bio To Be Bought By Lilly In Up To $1.5 Bln Cash Deal
Show 2 more
  1. BusinessEli Lilly agreed to buy Calytrix Bio in a deal that could be worth up to $1.5 billion in the latest transaction by the acquisitive US drug company
  2. OpenOutcrier$LLY (+0.6% pre) Lilly to buy Calytrix Bio for up to $1.5 billion